Of the 160 patients with BRCA1 or BRCA2 alteration, 128 had only an alteration in BRCA2 and 13 had only an alteration in BRCA1. The remaining patients had co-occurring alterations in other HR genes. 86 patients had alterations in ATM, and 89 had alterations in CDK12. The percentage of patients with these gene alterations that had measurable disease received prior taxane or had specific patterns of metastatic disease (bone only, visceral, other) were well balanced between the olaparib or control arms.

With regards to benefit with alterations in these four genes, patients with BRCA1 and/or BRCA2 alteration seemed to derive the greatest benefit from olaparib relative to control with respect to radiographic progression-free survival (rPFS), overall survival, response rate, PSA response, and circulating tumor cell conversion. Other HR gene alterations were too rare to conduct meaningful analysis on their relationship to clinical outcome. Importantly, RAD51C and FANCLalterations were not present in the PROfound cohort. 

Presented by: Johann de Bono, MD, Ph.D., Regius Professor of Cancer Research and a Professor in Experimental Cancer Medicine at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. He is also the Director of the Drug Development Unit

Written by: Alok Tewari, MD, Ph.D., Medical Oncologist at the Dana-Farber Cancer Institute, at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (#GU21), February 11th-February 13th, 2021

References:
1. Hussain M, Mateo J, Fizazi K, et al., Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer N Engl J Med 383, (2020):2345-2357

Related Content: 
Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Can Be Preselected to Maximize Benefit of Olaparib - Maha Hussain

(UroToday.com) The Decipher classifier may be applied to prostate tumor tissue to help predict which patients undergoing prostatectomy may benefit the most from post-operative radiotherapy. To evaluate this, the G-MINOR study enrolled patients with pT3+ and/or surgical margin positive disease at the time of prostatectomy who had a subsequent PSA drop to less than 0.1. Patients were randomized to a genomic testing arm or control arm, and treatment decisions were left to the patient and provider (not mandated by trial). Decipher results were obtained on all patients, but only 1 arm of the study received this information. All patients were also counseled on their CAPRA-S score. The endpoint of this study was to determine how Decipher results impact clinical decision making for adjuvant radiotherapy versus surveillance. The study schema is shown below. 

(UroToday.com) African American men have a 1.6-1.8-fold higher risk of developing prostate cancer, develop prostate cancer at a younger age, and tend to have more aggressive disease at diagnosis. Disparities in prostate cancer outcomes for these men are likely influenced by both socioeconomic and healthcare access issues, as well as genetic factors.  In this study, Dr. Khashab presented genomic data derived from a retrospective analysis of patients treated at a community-focused academic healthcare system in Texas that serves a higher percentage of Hispanic and African American patients with prostate cancer. 

(UroToday.com) In this discussion, Dr. Alumkal discussed two presentations looking at molecular correlates of response to apalutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) and data from the ACIS trial of androgen annihilation with abiraterone and apalutamide in chemotherapy naïve mCRPC. 

(UroToday.com) Pembrolizumab, an anti-PD-1 antibody, has antitumor activity as monotherapy in patients with heavily pre-treated, PD-L1 positive advanced prostate cancer as well as mCRPC patients regardless of PD-L1 expression status. KEYNOTE-365 is a 4-cohort study evaluating the combination of pembrolizumab in combination with multiple agents, as shown below. Results from Cohort B, the combination of pembrolizumab with docetaxel and prednisone, were previously presented at ESMO 2020 after a median follow-up of 20 months. In this presentation, Dr. Appleman shared updated data with a median time of follow-up of 32.4 months.  The study schema is shown below.